MEGIN Masterclass

Guidelines and Practical Considerations for Language Mapping in Clinical Cohorts using Magnetoencephalography (MEG)

Presented by Dr. Roozbeh Rezaie.

Abstract: “Since it’s adoption in clinical practice, much progress has been made in developing and optimizing MEG as a non-invasive tool for localizing language-specific cortex and determining hemispheric dominance for language, particularly in the context of surgical management of epilepsy and brain tumors. Here, Dr. Roozbeh Rezaie will review the utility of MEG as an alternative to traditional invasive diagnostic methods often considered as the “gold standard” techniques for identifying language-specific and determining laterality. Subsequently, we will discuss the application of appropriate MEG language-mapping protocols developed to reliably generate spatiotemporal profiles of language activity. In particular, emphasis will be placed on best-practices for executing validated MEG language-mapping paradigms in adult and pediatric populations, in a variety of scenarios. Furthermore, the practical aspects of analyzing MEG language mapping data will be discussed in detail, using clinical case studies, to illustrate the manner in which brain regions supporting linguistic functions are localized and judgements regarding hemispheric dominance are made. The overall objective of this didactic session will be to familiarize interested practitioners with the advantages (and limitations) of MEG as a functional neuroimaging technique for mapping language and, more importantly, serve as a guide for successfully acquiring and interpreting MEG language mapping data, in a clinical context.”

*The MEGIN Masterclasses content and speakers selected are only for information purposes and MEGIN does not endorse any applications or treatments mentioned.

**TRIUX™ neo is intended to non-invasively record brain activity, and when interpreted by trained physicians, to help localize these active areas. All other applications are scientific research in nature. Please contact MEGIN for further information.